[go: up one dir, main page]

BRPI1014802A2 - pró-fármacos de triptolida. - Google Patents

pró-fármacos de triptolida.

Info

Publication number
BRPI1014802A2
BRPI1014802A2 BRPI1014802A BRPI1014802A BRPI1014802A2 BR PI1014802 A2 BRPI1014802 A2 BR PI1014802A2 BR PI1014802 A BRPI1014802 A BR PI1014802A BR PI1014802 A BRPI1014802 A BR PI1014802A BR PI1014802 A2 BRPI1014802 A2 BR PI1014802A2
Authority
BR
Brazil
Prior art keywords
tryptolide
prodrugs
tryptolide prodrugs
Prior art date
Application number
BRPI1014802A
Other languages
English (en)
Inventor
Ashok K Saluja
Ingrid Gunda Georg
Rohit Chugh
Satish Prakash Patil
Selwyn M Vickers
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Publication of BRPI1014802A2 publication Critical patent/BRPI1014802A2/pt
Publication of BRPI1014802B1 publication Critical patent/BRPI1014802B1/pt
Publication of BRPI1014802B8 publication Critical patent/BRPI1014802B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/665Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
BRPI1014802A 2009-05-07 2010-05-07 profármacos de triptolida. BRPI1014802B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17624909P 2009-05-07 2009-05-07
US61/176,249 2009-05-07
PCT/US2010/034117 WO2010129918A1 (en) 2009-05-07 2010-05-07 Triptolide prodrugs

Publications (3)

Publication Number Publication Date
BRPI1014802A2 true BRPI1014802A2 (pt) 2016-04-05
BRPI1014802B1 BRPI1014802B1 (pt) 2020-09-24
BRPI1014802B8 BRPI1014802B8 (pt) 2021-05-25

Family

ID=42244313

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1014802A BRPI1014802B8 (pt) 2009-05-07 2010-05-07 profármacos de triptolida.

Country Status (17)

Country Link
US (1) US8507552B2 (pt)
EP (1) EP2427467B1 (pt)
JP (3) JP6000122B2 (pt)
KR (1) KR101821823B1 (pt)
CN (1) CN102596977B (pt)
AU (1) AU2010245669B2 (pt)
BR (1) BRPI1014802B8 (pt)
CA (2) CA2964631A1 (pt)
DK (1) DK2427467T3 (pt)
EA (1) EA021135B1 (pt)
ES (1) ES2552163T3 (pt)
MX (1) MX2011011776A (pt)
MY (1) MY160392A (pt)
PL (1) PL2427467T3 (pt)
PT (1) PT2427467E (pt)
SG (1) SG175885A1 (pt)
WO (1) WO2010129918A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9150600B2 (en) * 2009-05-07 2015-10-06 Regents Of The University Of Minnesota Triptolide prodrugs
ES2902651T3 (es) 2012-08-23 2022-03-29 Senestech Inc Reducción de la capacidad reproductiva de mamíferos
WO2014047783A1 (zh) * 2012-09-25 2014-04-03 鼎泓国际投资(香港)有限公司 含有雷公藤甲素及雷公藤甲素类衍生物和Bcl-2抑制剂的药物组合物及其应用
WO2014167581A2 (en) * 2013-04-01 2014-10-16 Laurus Labs Private Limited An improved process for the preparation of triptolide prodrugs
WO2017043613A1 (ja) * 2015-09-11 2017-03-16 ワイズエーシー株式会社 抗cd26抗体と他の抗癌剤とを組み合わせた癌治療用組成物
CN109942665B (zh) * 2018-04-02 2021-04-06 欣凯医药化工中间体(上海)有限公司 雷公藤内酯醇衍生物及其制备方法和应用
CN110551171B (zh) * 2018-05-31 2021-07-27 欣凯医药化工中间体(上海)有限公司 一种雷公藤内酯醇衍生物的制备方法
US20200085784A1 (en) 2018-09-13 2020-03-19 Minneamrita Therapeutics, LLC Methods to treat fibrosis, nash, and nafld
JP7702110B2 (ja) * 2020-04-28 2025-07-03 国立大学法人高知大学 ヒト膵癌オルガノイドを用いたマウスモデルの樹立
US20230303618A1 (en) 2020-08-21 2023-09-28 Reyoung Corporation Triptolide conjugates and uses thereof
CN115227829B (zh) * 2022-02-22 2023-10-13 成都中医药大学 酸敏感性适配体雷公藤甲素偶联物及应用
EP4676463A1 (en) 2023-03-09 2026-01-14 Minneamrita Therapeutics LLC Drug combination for treatment of pancreatic cancer
ES3035530T3 (en) 2023-03-09 2025-09-04 Minneamrita Therapeutics Llc Drug combination for the treatment of stomach cancer
WO2024187139A1 (en) 2023-03-09 2024-09-12 Minneamrita Therapeutics Llc Drug combination for treatment of gastric cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843452A (en) 1992-11-09 1998-12-01 Pharmagenesis, Inc. Immunotherapy composition and method
US5759550A (en) 1993-05-06 1998-06-02 Pharmagenesis, Inc. Method for suppressing xenograft rejection
US5609991A (en) 1995-02-10 1997-03-11 Morton International, Inc. Photoimageable composition having improved alkaline process resistance and tack-free surface for contact imaging
US5663335A (en) 1996-03-01 1997-09-02 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US5962516A (en) 1997-02-28 1999-10-05 Pharmagenesis, Inc. Immunosuppressive compounds and methods
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
CA2342901A1 (en) 1998-09-02 2000-03-09 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
US6548537B1 (en) * 1998-09-02 2003-04-15 Pharmagenesis, Inc. Triptolide prodrugs having high aqueous solubility
AU3365800A (en) 1999-02-16 2000-09-04 Board Of Trustees Of The Leland Stanford Junior University Combined therapy of diterpenoid triepoxides and trail for synergistic killing oftumor cells
WO2000063212A1 (en) 1999-04-16 2000-10-26 Chengdu Diao Pharmaceutical Group Company Limited Derivatives of triptolide, and preparation and uses thereof
US6294546B1 (en) 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6620843B2 (en) * 2001-01-19 2003-09-16 Pharmagenesis Anticancer treatment using triptolide prodrugs
CA2448795A1 (en) * 2001-03-15 2002-09-26 Pharmagenesis, Inc. Amino acid derivatives of triptolide compounds as immune modulators and anticancer agent
CA2470423C (en) * 2001-12-21 2011-03-15 Guilford Pharmaceuticals, Inc. Process for preparing water-soluble phosphonooxymethyl derivatives of alcohol and phenol
EP2468277A1 (en) 2002-05-31 2012-06-27 Pharmagenesis, Inc. Triptolide derivatives for modulation of apoptosis and immunosuppression
CN100398544C (zh) * 2002-09-18 2008-07-02 成都达远药物有限公司 高免疫抑制活性的水溶性雷公藤内酯醇衍生物及其应用
CN1726025A (zh) 2002-12-17 2006-01-25 泛华医药公司 作为免疫调节剂和抗癌剂的雷公藤内酯醇衍生物
CN1223595C (zh) 2002-12-27 2005-10-19 中国科学院上海药物研究所 雷公藤内酯醇衍生物及其应用
US6943259B2 (en) 2003-02-25 2005-09-13 Pharmagenesis, Inc. Halogenated triptolide derivatives as immunomodulators and anticancer agents
WO2005020887A2 (en) 2003-06-27 2005-03-10 Pharmagenesis, Inc. Method for treatment of severe acute respiratory syndrome
US7820834B2 (en) 2003-12-24 2010-10-26 Pharmagenesis, Inc. Triptolide 5,6-derivatives as immunomodulators and anticancer agents
JP5252765B2 (ja) 2003-12-26 2013-07-31 学校法人東京薬科大学 皮脂産生抑制剤及び皮脂腺発達抑制剤、並びに、皮膚外用剤
WO2005084365A2 (en) 2004-03-02 2005-09-15 Pharmagenesis, Inc. Triptolide lactone ring derivatives as immunomodulators and anticancer agents
WO2006012204A2 (en) 2004-06-25 2006-02-02 Pharmagenesis, Inc. Method for treatment of inflammatory disorders using triptolide compounds
WO2007025031A2 (en) * 2005-08-24 2007-03-01 Cephalon, Inc. Prodrugs of indanone and tetralone compounds
CN101049300A (zh) 2006-04-04 2007-10-10 中国科学院上海药物研究所 包含雷公藤内酯醇衍生物的药物组合物、其剂型和应用
CN101611009A (zh) * 2006-07-25 2009-12-23 伊维沃制药股份有限公司 喹啉衍生物
EP2133355A4 (en) * 2007-03-06 2011-12-28 Eisai R&D Man Co Ltd COMPOSITION WITH A CHLOROMETHYPHOSPHATE DERIVATIVE WITH INCREASED STABILITY AND METHOD FOR THE PRODUCTION THEREOF
FI20070574A0 (fi) * 2007-07-30 2007-07-30 Kuopion Yliopisto Vesiliukoinen propofolin etylideenifosfaatti-aihiolääke
WO2009023201A1 (en) 2007-08-16 2009-02-19 Myelorx Llc Rigid derivatives of triptolide as anticancer, immune suppressant, anti-fibrosis, and cns protectant agents

Also Published As

Publication number Publication date
BRPI1014802B1 (pt) 2020-09-24
KR20120015339A (ko) 2012-02-21
MY160392A (en) 2017-03-15
ES2552163T3 (es) 2015-11-26
CA2964631A1 (en) 2010-11-11
US8507552B2 (en) 2013-08-13
CN102596977B (zh) 2016-06-29
PL2427467T3 (pl) 2016-04-29
EP2427467A1 (en) 2012-03-14
KR101821823B1 (ko) 2018-01-24
AU2010245669B2 (en) 2015-11-26
JP2016065099A (ja) 2016-04-28
MX2011011776A (es) 2012-08-03
JP2014185181A (ja) 2014-10-02
CA2760953C (en) 2017-05-30
WO2010129918A1 (en) 2010-11-11
SG175885A1 (en) 2011-12-29
EP2427467B1 (en) 2015-08-05
BRPI1014802B8 (pt) 2021-05-25
US20120238529A1 (en) 2012-09-20
EA021135B1 (ru) 2015-04-30
CN102596977A (zh) 2012-07-18
PT2427467E (pt) 2015-11-19
EA201190293A1 (ru) 2012-11-30
JP6000122B2 (ja) 2016-09-28
DK2427467T3 (en) 2015-11-09
AU2010245669A1 (en) 2011-12-01
HK1168107A1 (en) 2012-12-21
CA2760953A1 (en) 2010-11-11
WO2010129918A8 (en) 2011-01-20
JP2012526148A (ja) 2012-10-25

Similar Documents

Publication Publication Date Title
BRPI1009415A2 (pt) escova de dentes.
DK2462134T3 (da) N1-sulfonyl-5-fluorpyrimidinonderivater
DK2414015T3 (da) Laryngoskopsystem
BRPI1014802A2 (pt) pró-fármacos de triptolida.
BRPI1007047A2 (pt) Biorrefino irganosolv de cana-de-açúcar inteira.
BRPI1005525A2 (pt) compostos de azaazuleno
FI20095302A0 (fi) Luminesenssimääritysmenetelmä
BR112012005598A2 (pt) profármacos de guanfacina
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
IT1396487B1 (it) Convogliatore.
FI20095891A0 (fi) Polttomoottorisovitelma
BRPI1008921A2 (pt) cabeçote de impressão
FI20095754A0 (fi) Tuloilmalaite
BRPI1016192A2 (pt) derivados de soxazol.
FR2947857B1 (fr) Agencement de deshuileur
FR2941674B1 (fr) Nacelle de turboreacteur.
EP2509287A4 (en) SLIDING AND TILTING MECHANISM
BRPI0924638A2 (pt) ativação de função.
ES1070429Y (es) Traspaleta mejorada
DE602010000025D1 (de) Fahrzeugsitzgurtvorrichtung
BR112012006693A2 (pt) combinação
BR112012003616A2 (pt) metilpirroloprimidinacarboxamidas
BRPI1008675A2 (pt) grânulos.
EP2392475A4 (en) NECESSARY TO PAINT

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/05/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF